Compounds useful as RET inhibitors
US11680068B2 · kind B2 · utility
0Cited by
23References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 6, 2022 |
| Grant date | Jun 20, 2023 |
| Priority date | — |
| Expiry date | May 6, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.